No connection

Search Results

MENS vs OGI

MENS
Jyong Biotech Ltd.
BEARISH
Price
$2.79
Market Cap
$212.1M
Sector
Healthcare
AI Confidence
95%
OGI
Organigram Global Inc.
BEARISH
Price
$1.52
Market Cap
$209.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
MENS
--
OGI
13.82
Forward P/E
MENS
--
OGI
84.44
P/B Ratio
MENS
-8.91
OGI
0.77
P/S Ratio
MENS
--
OGI
0.75
EV/EBITDA
MENS
-121.13
OGI
47.95

Profitability

Gross Margin
MENS
0.0%
OGI
35.61%
Operating Margin
MENS
0.0%
OGI
-5.38%
Profit Margin
MENS
0.0%
OGI
6.49%
ROE
MENS
--
OGI
4.64%
ROA
MENS
-5.44%
OGI
-1.47%

Growth

Revenue Growth
MENS
--
OGI
48.7%
Earnings Growth
MENS
--
OGI
--

Financial Health

Debt/Equity
MENS
--
OGI
0.02
Current Ratio
MENS
0.62
OGI
2.73
Quick Ratio
MENS
0.62
OGI
0.62

Dividends

Dividend Yield
MENS
--
OGI
--
Payout Ratio
MENS
0.0%
OGI
0.0%

AI Verdict

MENS BEARISH

MENS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a critical lack of fundamental value. The company reports a negative Price-to-Book ratio of -8.91, indicating negative shareholders' equity, and a Current Ratio of 0.62, signaling an immediate liquidity crisis. With zero reported revenue and a catastrophic 95% price decline over the last six months, the stock appears to be in a speculative death spiral. Recent short-term gains are likely volatility-driven 'dead cat bounces' rather than a fundamental recovery.

Strengths
Recent short-term price recovery (+40.9% in 1 month)
Small market cap allows for high volatility spikes
Operates in the high-growth Healthcare/Biotech sector
Risks
Negative book value indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.62)
Complete absence of revenue and profit margins
OGI BEARISH

OGI exhibits severe financial fragility, highlighted by a weak Piotroski F-Score of 2/9 and a negative operating margin of -5.38%. While the stock appears undervalued relative to its Graham Number ($2.21) and Price-to-Book ratio (0.77), the intrinsic value is significantly lower at $0.77. Strong top-line revenue growth of 48.7% is currently offset by a poor earnings track record and a concerning spike in Forward P/E (from 13.82 to 84.44), suggesting a projected collapse in earnings. The company is essentially a speculative play on revenue growth that has yet to prove operational sustainability.

Strengths
Strong YoY revenue growth of 48.70%
Very low leverage with a Debt/Equity ratio of 0.02
Trading below book value (P/B 0.77)
Risks
Critical financial health weakness (Piotroski F-Score 2/9)
Negative operating margin (-5.38%) indicating core business losses
Severe earnings volatility with an average surprise of -949.02% over the last 4 quarters

Compare Another Pair

MENS vs OGI: Head-to-Head Comparison

This page compares Jyong Biotech Ltd. (MENS) and Organigram Global Inc. (OGI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile